Provider QP30-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Hereditary transthyretin-mediated (hATTR) Amyloidosis Neuropathy Read More
Provider QP32-19 Pharmacy Benefit Exclusion for Glyrx-PF, Libtayo, Lumoxiti, Onpattro, Poteligeo, and Xerava Read More
Provider QP31-19 Change to Outpatient Therapies Prior Authorization Requirements for Medicare Advantage Subscribers Read More
Provider QP29-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Arikayce Read More
Provider QP24-19 New Behavioral Health Coding for Early Intensive Behavioral Intervention (EIBI) Services for Commercial Lines of Business Read More
